Results 171 to 180 of about 693,900 (279)

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA Oncol
Haggstrom L, Lee YC, Barretina-Ginesta MP, Jaeger A, Woelber L, Woopen H, Rhind M, Frenel JS, Aanum A, Bischof K, Mongillo M, Brodsky AL, Ledermann J, Ghezelayagh TS, Boere I, Kaiser S, Maximiano C, Rosengarten O, Safra T, Pertejo A, Cecere S, Ray-Coquard I, Lheureux S, Glasspool R, Gil-Martin M, Tookman L, Kim SI, Mittelstadt S, Corbellas Aparicio M, Palacio I, Martin-Lorente C, Kristeleit R, de la Cueva H, Ottevanger N, Quindós Varela M, Yoshida H, Link T, Gaba L, Marquina G, Burdett N, Johannet P, Reichenbach J, Park-Simon TW, Klecker PH, González-Martín A, Marth C, Liebrich C, Dzotsenidze L, Heublein S, Kasherman L, Perez C, Masvidal M, Guillén Sentís P, de Gregorio N, Hemptenmacher F, Hilpert F, Sehouli J, Scott C, Tucker KM, Dong J, Fortuno C, Spurdle AB, Friedlander M, Gynecologic Cancer InterGroup Collaboration Into Exceptional Responders to PARP Inhibitors (GCIG-CERP).   +63 more
europepmc   +1 more source

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]

Front Oncol
Dima G, Di Nunno V, Aprile M, Gatto L, Tosoni A, Argento CM, Margotti M, Bartolini S, Franceschi E.   +8 more
europepmc   +1 more source

Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives. [PDF]

Cancer Biol Med
Yu J, Li M, Zhu Y, Wang S, Jiang Y, Cui W, Wu L.   +6 more
europepmc   +1 more source

A PARP inhibitorok hatásának vizsgálata humán keratinociták differenciációjára

A poli(ADP-riboz)iláció egy poszttranszlációs fehérje módosítás, amelyet a poli(ADP-ribóz) polimeráz (PARP) enzimek végeznek. A PARP aktivitás számos biológiai folyamat szabályozásában szerepel, többek között a DNS hibajavítás, transzkripció és ...
Maczkó, Eszter
core  

Synthetic lethality between PBRM1 deficiency and PARP inhibitors: exploiting G2/M checkpoint arrest in colorectal cancer. [PDF]

Mol Med
Islam MT, Quan H, Chen S, Xu Z, Guo M, Wang Z.   +5 more
europepmc   +1 more source

Decoding neuronal vulnerability: Multidimensional analysis of D1R‐ and D2R‐ medium‐sized spiny neurons in Huntington's disease

Brain Pathology, EarlyView.
D1R and D2R MSNs show distinct responses to Huntington's pathology. G&T‐sequencing of pre‐symptomatic MSNs reveals global LINE‐1 downregulation. While D1R‐MSNs display early transcriptomic changes (OXPHOS/translation upregulation) and reduced mutant huntingtin aggregation, D2R‐MSNs exhibit higher nuclear mHTT accumulation and greater CAG somatic ...
Guendalina Bergonzoni, Miguel Pellegrini, Aurora Savino, Martina Lazioli, Sarah Geurs, Lorenzo Graziani, Denise Ferrarini, Solaleh Khoramian Tusi, Esaria Oliver, Jarne Geurts, Sara Vinciguerra, Michele Tebaldi, Takshashila Tripathi, Isabella Pesce, Valeria Poli, Alessandro Romanel, Rosario Moratalla, Thierry Voet, Jasmin Morandell, Remo Sanges, Vanessa C. Wheeler, Erik Dassi, Marta Biagioli   +22 more
wiley   +1 more source

PARP Inhibitors in Metastatic Prostate Cancer: Bridging Biomarker Complexity and Clinical Decision-Making Through a Pragmatic Treatment Framework. [PDF]

Cancers (Basel)
Abahssain H, Sabri O, Lemaire A, Souadka A.   +3 more
europepmc   +1 more source

PARP inhibitors synergize with abiraterone [PDF]

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors. [PDF]

Front Immunol
He R, Wei Y, Niu J, Huang J, Wu R, Gu K, Wu A, Qiu L.   +7 more
europepmc   +1 more source